Last reviewed · How we verify

anti-VEGF agent — Competitive Intelligence Brief

anti-VEGF agent (anti-VEGF agent) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic agent (VEGF inhibitor). Area: Oncology, Ophthalmology.

marketed Anti-angiogenic agent (VEGF inhibitor) VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors Oncology, Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

anti-VEGF agent (anti-VEGF agent) — Medical University of Vienna. Anti-VEGF agents block vascular endothelial growth factor signaling to inhibit abnormal blood vessel formation and reduce tumor angiogenesis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
anti-VEGF agent TARGET anti-VEGF agent Medical University of Vienna marketed Anti-angiogenic agent (VEGF inhibitor) VEGF (Vascular Endothelial Growth Factor) and/or VEGF receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic agent (VEGF inhibitor) class)

  1. Medical University of Vienna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). anti-VEGF agent — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-vegf-agent. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: